Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junqi Niu

Showing results (251-260 of 280) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I studyNingning Zhang, Tian Liu, Ming Luo, et al.
Journal of Clinical and Translational Hepatology|March 27, 2023
96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B PatientsZhihong Liu, Qinglong Jin, Yuexin Zhang, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 24, 2017
Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis BRui Yu, Deming Tan, Qin Ning, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled studyJian Sun, Qing Xie, Deming Tan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 24, 2024
Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis BShi Liu, Grace Lai-Hung Wong, Rong Fan, et al.
Journal of Gastroenterology and Hepatology|October 30, 2014
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patientsXieer Liang, Jun Cheng, Yongtao Sun, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 13, 2020
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trialYanhang Gao, Fei Kong, Guangming Li, et al.
Journal of Gastroenterology and Hepatology|January 25, 2021
Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trialFei Kong, Xiaoyu Wen, Xiaofeng Wen, et al.
Gastroenterology|February 12, 2019
Incidence and Etiology of Drug-Induced Liver Injury in Mainland ChinaTao Shen, Yingxia Liu, Jia Shang, et al.
Hepatology International|July 23, 2025
A randomized, phase Ib trial of recombinant human serum albumin in cirrhotic patients with ascitesXinrui Wang, Wanyu Li, Fei Kong, et al.
Pageof 28

Showing results (251-260 of 280) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I studyNingning Zhang, Tian Liu, Ming Luo, et al.
Journal of Clinical and Translational Hepatology|March 27, 2023
96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B PatientsZhihong Liu, Qinglong Jin, Yuexin Zhang, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 24, 2017
Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis BRui Yu, Deming Tan, Qin Ning, et al.
Hepatology (Baltimore, Md.)|January 3, 2014
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled studyJian Sun, Qing Xie, Deming Tan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 24, 2024
Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis BShi Liu, Grace Lai-Hung Wong, Rong Fan, et al.
Journal of Gastroenterology and Hepatology|October 30, 2014
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patientsXieer Liang, Jun Cheng, Yongtao Sun, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 13, 2020
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trialYanhang Gao, Fei Kong, Guangming Li, et al.
Journal of Gastroenterology and Hepatology|January 25, 2021
Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trialFei Kong, Xiaoyu Wen, Xiaofeng Wen, et al.
Gastroenterology|February 12, 2019
Incidence and Etiology of Drug-Induced Liver Injury in Mainland ChinaTao Shen, Yingxia Liu, Jia Shang, et al.
Hepatology International|July 23, 2025
A randomized, phase Ib trial of recombinant human serum albumin in cirrhotic patients with ascitesXinrui Wang, Wanyu Li, Fei Kong, et al.
Pageof 28